FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion
0,3699 USD
+11,35 %+0,0377
15. Nov, 02:00:00 Uhr,
Nasdaq
Kommentare 210
S
SuperLongholdn,
29.06.2023 19:41 Uhr
0
👀☕
S
SuperLongholdn,
29.06.2023 19:40 Uhr
0
👀☕
Summer.76,
26.06.2023 14:13 Uhr
0
FibroGen's drug fails late-stage trial for treating lung disease
https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-lung-disease-treatment-fails-late-stage-trial-2023-06-26/
Summer.76,
26.06.2023 14:13 Uhr
0
https://www.globenewswire.com/news-release/2023/06/26/2694309/0/en/FibroGen-Announces-Topline-Results-from-Phase-3-ZEPHYRUS-1-Study-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html
Summer.76,
07.06.2023 14:42 Uhr
0
https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-neuromuscular-disorder-drug-fails-late-stage-study-2023-06-07/
FibroGen's neuromuscular disorder drug fails in late-stage study
Summer.76,
18.05.2023 16:39 Uhr
0
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-topline-results-china-pivotal-phase
• Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa
• Plan to file supplemental New Drug Application in China
Summer.76,
09.05.2023 6:12 Uhr
0
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
https://www.globenewswire.com/news-release/2023/05/08/2663795/33525/en/FibroGen-Enters-into-Exclusive-License-for-FOR46-with-Fortis-Therapeutics.html
Summer.76,
09.05.2023 6:12 Uhr
0
FibroGen Reports First Quarter 2023 Financial Results
https://finance.yahoo.com/news/fibrogen-reports-first-quarter-2023-200100063.html
Summer.76,
01.05.2023 13:59 Uhr
0
https://beststocks.com/fibrogen-secures-nondilutive-term-loan-financ/
Summer.76,
27.02.2023 22:21 Uhr
0
https://seekingalpha.com/news/3941377-fibrogen-gaap-eps-of-0_70-beats-0_25-revenue-of-34_37m-beats-10_42m
FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M
Summer.76,
27.02.2023 22:14 Uhr
0
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
https://www.globenewswire.com/news-release/2023/02/27/2616460/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html
• Topline Data from Five Pivotal Phase 3 Trials in 2023
• Total Company Revenue $140.7 Million in 2022
• Continued Strong Roxadustat Volume Growth in China
Summer.76,
31.01.2023 16:52 Uhr
1
William Blair Upgrades FibroGen to Outperform
https://www.benzinga.com/news/23/01/30636166/william-blair-upgrades-fibrogen-to-outperform
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | EVOTEC Hauptdiskussion | +39,37 % | |
| 2 | NEL ASA Hauptdiskussion | +6,71 % | |
| 3 | Dax Prognose | +1,23 % | |
| 4 | PENINSULA ENERGY LTD. Hauptdiskussion | +1,79 % | |
| 5 | GAMESTOP Hauptdiskussion | +3,40 % | |
| 6 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | |
| 7 | FRESENIUS SE Hauptdiskussion | +0,05 % | |
| 8 | Samsung SDI eine der innovativsten Globalplayer in Sachen in Sachen Energiespeicher. | +3,04 % | |
| 9 | RENESOLA LTD. Hauptdiskussion | -1,72 % | |
| 10 | Brainchip Klassengruppe | -8,68 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | EVOTEC Hauptdiskussion | +39,37 % | |
| 2 | NEL ASA Hauptdiskussion | +6,71 % | |
| 3 | PENINSULA ENERGY LTD. Hauptdiskussion | +1,79 % | |
| 4 | GAMESTOP Hauptdiskussion | +3,40 % | |
| 5 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | |
| 6 | FRESENIUS SE Hauptdiskussion | +0,05 % | |
| 7 | Samsung SDI eine der innovativsten Globalplayer in Sachen in Sachen Energiespeicher. | +3,04 % | |
| 8 | RENESOLA LTD. Hauptdiskussion | -1,72 % | |
| 9 | Brainchip Klassengruppe | -8,68 % | |
| 10 | Super Micro Computer Hauptdiskussion | -11,41 % | Alle Diskussionen |